Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Palbociclib slows tumour growth in early breast cancer

Research published in the Journal of Clinical Oncology has shown that palbociclib, taken with hormone therapy, has marked success in slowing tumour growth in early breast cancer.

A doctor checking a mamogram for breast cancer


Taking the CDK4/6 inhibitor palbociclib on top of hormone therapy can slow the progress of tumour growth in women with early breast cancer, researchers have found

Adding the CDK4/6 inhibitor palbociclib to hormone therapy can slow or stop tumour growth in women with early breast cancer, a study in the Journal of Clinical Oncology has shown (6 December 2018)[1].

The 14-week trial involved 307 postmenopausal women with oestrogen receptor-positive primary breast cancer with a tumour of at least 2cm. Patients were randomly assigned to one of four groups: letrozole alone for 14 weeks, letrozole and palbociclib for 14 weeks, or letrozole or palbociclib alone for two weeks followed by 12 weeks of letrozole and palbociclib.

Biopsies at weeks 2 and 14 showed significant suppression of malignant cell proliferation. At week 14, 90% of those who received palbociclib plus letrozole had complete cell-cycle arrest compared with 59% on letrozole alone.

However, overall tumour volume did not differ between groups, which the authors said could be owing to reduced apoptosis in the palbociclib groups.

They concluded that the addition of palbociclib to letrozole markedly enhanced the suppression of malignant cell proliferation, but did not increase tumour shrinkage.

“Correlating biomarkers of antiproliferative response in the context of a randomised neoadjuvant study will be important in determining which patients may derive the most benefit from CDK4/6 inhibitors in ongoing adjuvant studies in early [breast cancer],” the authors said.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206053

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.